Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cara Therapeutics Inc T.CARA


Primary Symbol: CARA

Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.


NDAQ:CARA - Post by User

Comment by SkyeCairnson Apr 01, 2016 2:39pm
265 Views
Post# 24721120

RE:RE:RE:Like this too but don't understand share structure ...

RE:RE:RE:Like this too but don't understand share structure ...Additional info of captial structure of Cara from IPO prospectus:

Upon completion of the Offering, the Company will have two classes of issued and outstanding shares: Subordinate Voting
Shares and multiple voting shares (‘‘Multiple Voting Shares’’, and together with the Subordinate Voting Shares, the
‘‘Shares’’). The Multiple Voting Shares will be held by Fairfax Financial Holdings Limited and its affiliates (‘‘Fairfax’’) and
the Phelan family through Cara Holdings Limited and its affiliates (‘‘Cara Holdings’’, and together with Fairfax, the
‘‘Principal Shareholders’’), either directly or indirectly. The Subordinate Voting Shares and the Multiple Voting Shares are
substantially identical with the exception of the voting, pre-emptive and conversion rights attached to the Multiple Voting
Shares. Each Subordinate Voting Share is entitled to one vote and each Multiple Voting Share is entitled to 25 votes on all
matters.
<< Previous
Bullboard Posts
Next >>